Ginkgo Bioworks Stock News

Sizing positions correctly is a cornerstone of successful investing, especially when dealing with penny stocks. The unique nature of penny stocks, with their potential for substantial gains, requires

Ginkgo Bioworks is trying to make good on its promises of scaling up. It's adding plenty of new programs, but its revenue is lagging.

Pfizer is a rebound candidate that pays a hefty dividend while you wait. AbbVie has been broadening its product offerings to become more diversified.

Ginkgo Bioworks is aiming to play a key role in drug development. And there's a solid argument for why it could be hugely successful one day.

Ginkgo Bioworks' fourth-quarter results missed Wall Street's revenue and earnings estimates. The company's full-year 2024 revenue guidance was also well below analysts' consensus estimate.

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.04 per share a year ago.

Ginkgo's cell programming process helps businesses launch products and improve existing processes. The company has partnered with many top names in the healthcare industry for this purpose.

Analysts are bullish, on average, regarding both Ginkgo Bioworks and Iovance Biotherapeutics. Ginkgo Bioworks' cost-cutting and manufacturing scaling capabilities are being put to the test.

You can't say Cathie Wood is afraid to make big bets. The investing guru is more than willing to lay it all on the line for stocks she believes in.

The average analyst following Ginkgo Bioworks thinks the stock can climb 140% from recent prices over the next 12 months or so. The consensus price target on Intellia Therapeutics suggests it can more

Healthcare stocks trudged through what was a terrible 2023 for the sector. While the S&P 500 rose by 24% during 2023, the healthcare sector managed paltry returns of 0.3%.

Cathie Wood bought shares of Meta Platforms, Recursion Pharmaceuticals, and Ginkgo Bioworks this week. Shares of Meta have more than tripled since bottoming out in late 2022.

Eli Lilly's valuation is through the roof, but it's not just hot air. Ginkgo Bioworks could become a great long-term pickup.

Cathie Wood has loaded up her portfolio with tomorrow's potential healthcare game changers. The superstar investor's commitment to innovation helped her flagship fund jump more than 60% last year.

Ginkgo Bioworks is a cell programming specialist that has partnered with many big companies. It is in a very early stage, but has a lot of promising opportunities in the long run.